The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.17907
Abstract: Trastuzumab, an anti-ErbB2 humanized antibody, brings benefit to patients with ErbB2-amplified metastatic breast cancers. However, the resistance to trastuzumab is common. Our previously reported H2-18, an anti-ErbB2 antibody, potently induced programmed cell death in trastuzumab-resistant… read more here.
Keywords: anti erbb2; gdc 0941; breast; breast cancer ... See more keywords
Enhancement of Insulin Sensitivity Contributes to Polychlorinated Biphenyl-126–Induced Hepatic Steatosis and Injury
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-629-p
Abstract: Background: In the last decades, the prevalence of diabetes and related diseases of metabolic disorders has a dramatic increase. The global prevalence of diabetes and its related diseases is closely associated with the exposure to… read more here.
Keywords: hepatic steatosis; 126 induced; pcb 126; gdc 0941 ... See more keywords
Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.958443
Abstract: Although advances in diagnostics and therapeutics have prolonged the survival of triple-negative breast cancer (TNBC) patients, metastasis, therapeutic resistance, and lack of targeted therapies remain the foremost hurdle in the effective management of TNBC. Thus,… read more here.
Keywords: triple negative; breast cancer; gdc 0941; tnbc ... See more keywords